CYTK Quote, Financials, Valuation and Earnings

Mirum Pharmaceuticals has a net margin of -34674.95% compared to Cytokinetics's net margin of -15.75%. Cytokinetics's return on equity of -- beat Mirum Pharmaceuticals's return on equity of -41.13%.

Cytokinetics has a consensus price target of $81.71, signalling upside risk potential of 68.36%. On the other hand Mirum Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 49.4%. Given that Cytokinetics has higher upside potential than Mirum Pharmaceuticals, analysts believe Cytokinetics is more attractive than Mirum Pharmaceuticals.

Cytokinetics has a beta of 0.796, which suggesting that the stock is 20.368% less volatile than S&P 500. In comparison Mirum Pharmaceuticals has a beta of 1.200, suggesting its more volatile than the S&P 500 by 19.974%.

Cytokinetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mirum Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytokinetics pays -- of its earnings as a dividend. Mirum Pharmaceuticals pays out -- of its earnings as a dividend.

Cytokinetics quarterly revenues are $463K, which are smaller than Mirum Pharmaceuticals quarterly revenues of $90.4M. Cytokinetics's net income of -$160.5M is lower than Mirum Pharmaceuticals's net income of -$14.2M. Notably, Cytokinetics's price-to-earnings ratio is -- while Mirum Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics is 1,612.94x versus 6.47x for Mirum Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen has a net margin of -34674.95% compared to Cytokinetics's net margin of -1141.73%. Cytokinetics's return on equity of -- beat Ocugen's return on equity of -136.91%.

Cytokinetics has a consensus price target of $81.71, signalling upside risk potential of 68.36%. On the other hand Ocugen has an analysts' consensus of -- which suggests that it could grow by 770.23%. Given that Ocugen has higher upside potential than Cytokinetics, analysts believe Ocugen is more attractive than Cytokinetics.

Cytokinetics has a beta of 0.796, which suggesting that the stock is 20.368% less volatile than S&P 500. In comparison Ocugen has a beta of 3.823, suggesting its more volatile than the S&P 500 by 282.261%.

Cytokinetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytokinetics pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.

Cytokinetics quarterly revenues are $463K, which are smaller than Ocugen quarterly revenues of $1.1M. Cytokinetics's net income of -$160.5M is lower than Ocugen's net income of -$13M. Notably, Cytokinetics's price-to-earnings ratio is -- while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics is 1,612.94x versus 40.09x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.

Rezolute has a net margin of -34674.95% compared to Cytokinetics's net margin of --. Cytokinetics's return on equity of -- beat Rezolute's return on equity of --.

Cytokinetics has a consensus price target of $81.71, signalling upside risk potential of 68.36%. On the other hand Rezolute has an analysts' consensus of $9.67 which suggests that it could grow by 194.79%. Given that Rezolute has higher upside potential than Cytokinetics, analysts believe Rezolute is more attractive than Cytokinetics.

Cytokinetics has a beta of 0.796, which suggesting that the stock is 20.368% less volatile than S&P 500. In comparison Rezolute has a beta of 1.011, suggesting its more volatile than the S&P 500 by 1.093%.

Cytokinetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rezolute offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytokinetics pays -- of its earnings as a dividend. Rezolute pays out -- of its earnings as a dividend.

Cytokinetics quarterly revenues are $463K, which are larger than Rezolute quarterly revenues of --. Cytokinetics's net income of -$160.5M is lower than Rezolute's net income of -$15.4M. Notably, Cytokinetics's price-to-earnings ratio is -- while Rezolute's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics is 1,612.94x versus -- for Rezolute. Usually stocks with elevated PS ratios are considered overvalued.

Scholar Rock Holding has a net margin of -34674.95% compared to Cytokinetics's net margin of --. Cytokinetics's return on equity of -- beat Scholar Rock Holding's return on equity of --.

Cytokinetics has a consensus price target of $81.71, signalling upside risk potential of 68.36%. On the other hand Scholar Rock Holding has an analysts' consensus of $46.38 which suggests that it could grow by 1.79%. Given that Cytokinetics has higher upside potential than Scholar Rock Holding, analysts believe Cytokinetics is more attractive than Scholar Rock Holding.

Cytokinetics has a beta of 0.796, which suggesting that the stock is 20.368% less volatile than S&P 500. In comparison Scholar Rock Holding has a beta of 0.578, suggesting its less volatile than the S&P 500 by 42.249%.

Cytokinetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Scholar Rock Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytokinetics pays -- of its earnings as a dividend. Scholar Rock Holding pays out -- of its earnings as a dividend.

Cytokinetics quarterly revenues are $463K, which are larger than Scholar Rock Holding quarterly revenues of --. Cytokinetics's net income of -$160.5M is lower than Scholar Rock Holding's net income of -$64.5M. Notably, Cytokinetics's price-to-earnings ratio is -- while Scholar Rock Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics is 1,612.94x versus 92.18x for Scholar Rock Holding. Usually stocks with elevated PS ratios are considered overvalued.